Business, energy, technology, markets and global industry news from Business News Today

asthma

PharmaDeviceNews asthma
Pharma & Biotech

Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?

Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More
Representative image of a clinician reviewing lung CT scans and noninvasive sputum-based testing, as bioAffinity Technologies reports rising CyPath Lung adoption and growing interest in early lung cancer diagnostic tools.
Medical Devices & Diagnostics

Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question

CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.

Read More
Representative image: Chance Pharmaceuticals’ CXG87 asthma inhalation therapy filing in China highlights how improved dry powder inhaler design could reshape respiratory drug delivery and asthma control.
Pharma & Biotech

Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?

Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.

Read More
Pharma & Biotech

Cipla just cracked a $1.5bn U.S. inhaler market. Here’s why it matters

Find out how Cipla’s U.S. FDA approval for generic Ventolin HFA strengthens its respiratory portfolio and inhaler manufacturing strategy.

Read More
Pharma & Biotech

What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma

AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.

Read More
Representative image of an inhaler used in asthma and COPD treatment. GSK’s Trelegy Ellipta has become the first approved single inhaler triple therapy for both conditions in China.
Pharma & Biotech

GSK’s Trelegy Ellipta becomes China’s first approved triple therapy for both asthma and COPD

GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the

Read More
Pharma & Biotech

Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?

Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.

Read More
Representative image illustrating the rising focus on U.S. drug pricing reform, as pharmaceutical companies like GSK move to expand access to asthma and COPD medicines through lower costs and direct purchasing models.
Pharma & Biotech

GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs

GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies

Read More